Table 2.
Univariate analysis of overall survival in patients with hepatocellular carcinoma (n = 537).
| Overall survival |
||
|---|---|---|
| HR (95% CI) | P | |
| Sex | ||
| Male | 1.00 | |
| Female | 1.19 (0.57–2.73) | 0.567 |
| Age | ||
| <50 | 1.00 | |
| ≥50 | 1.39 (0.377–4.10) | 0.659 |
| Serum AFP level (μg /l) | ||
| <20 | 1.00 | |
| ≥20 | 1.09 (0.38-3.07) | 0.961 |
| Serum HBsAg | ||
| Negative | 1.00 | |
| Positive | 1.66 (1.17–2.82) | 0.031 |
| Serum HBeAg | ||
| Negative | 1.00 | |
| Positive | 2.16(1.34-5.14) | 0.027 |
| Tumor size | ||
| ≤2 cm | 1.00 | |
| >2 cm | 0.81 (0.44-3.56) | 0.424 |
| Histological grade | ||
| Well | 1.00 | |
| Moderate | 1.42 (0.46-8.84) | 0.683 |
| Poor | 1.39 ( 0.83-8.16) | 0.514 |
| Liver cirrhosis | ||
| Absent | 1.00 | |
| Present | 1.67 (0.78-3.44) | 0.047 |
| Tumor capsule | ||
| Intact | 1.00 | |
| Absent or not intact | 1.37 (0.63–3.56) | 0.217 |
| Intrahepatic metastasis | ||
| Not observed | 1.00 | |
| Observed | 2.39 (147-6.13) | 0.039 |
| TNM stage | ||
| I + II | 1.00 | |
| III + IV | 2.58 (1.31-5.78) | 0.021 |
| PP2Ac expression | ||
| Low (≤10%) | 1.00 | |
| High (>10%) | 2.86 (1.25–6.44) | 0.015 |
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
Significant P values are marked in bold.